Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

Author(s)Vera Pervitsky, PharmD, BCOP, BCPS, Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA, Mimi Lo, PharmD, BCOP, BCPS

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Treatment with CPX-351 may result in lower initial complete remission rates but better survival outcomes after stem cell transplantation compared with the 7+3 regimen in younger adult patients with therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.